In murine models, administration of LCN2 increased bone Fgf23 mRNA expression and raised systemic FGF23 levels, supporting the existence of a kidney-to-bone axis whereby LCN2 may drive FGF23 excess in CKD [132]. Here, FGF23 is linked to chronic kidney disease.